{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Required Actions and Follow up Assessments following ANY Liver Stopping Event', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study intervention.', 'Make every attempt to carry out liver event', 'follow-up assessments at the central', 'Report the event to the Medical Monitor', 'laboratory as described below:', 'within 24 hours.', 'Viral hepatitis serology, including:', 'Complete the liver event eCRF and complete', 'an SAE data collection tool if the event also', 'Hepatitis A immunoglobulin M (IgM)', 'meets the criteria for an SAE\u00b2.', 'antibody;', 'Complete the liver imaging and/or liver biopsy', 'HBsAg and hepatitis B core', 'eCRFs if these tests are performed.', 'antibody;', 'Perform liver event follow up assessments.', 'Hepatitis C RNA;', 'Monitor the participant until liver chemistries', 'Hepatitis E IgM antibody.', 'resolve, stabilise, or return to within baseline', 'Cytomegalovirus IgM antibody.', '(see MONITORING below).', 'Epstein-Barr viral capsid antigen IgM', 'Do not restart participant with study', 'antibody (or if unavailable, obtain', 'intervention unless allowed per protocol and', 'heterophile antibody or monospot testing).', 'VSLC approval is granted (refer to Section', '11.9.2).', 'Syphilis screening.', 'If restart is not allowed or not granted,', 'Drugs of abuse screen, including alcohol.', 'permanently discontinue study intervention', 'Serum acetaminophen adduct HPLC', 'and may continue participant in the study for', 'assay (quantifies potential acetaminophen', 'any protocol specified follow up assessments.', 'contribution to liver injury in participants', 'with definite or likely acetaminophen use', 'in the preceding week [James, 2009]).', 'The site must contact the Medical Monitor', 'MONITORING:', 'when this test is required.', 'Make every reasonable attempt to have', 'Blood sample for pharmacokinetic (PK)', 'participants return to clinic within 24 hours for', 'analysis, obtained within 60 hours of last', 'repeat liver chemistries (include ALT, AST,', 'dose4.', 'alkaline phosphatase, bilirubin) and perform', 'liver event follow up assessments.', 'Serum CPK and lactate dehydrogenase', '(LDH).', 'Monitor participants twice weekly until liver', 'chemistries resolve, stabilise or return to', 'Gamma glutamyl transferase [GGT],', 'within baseline.', 'glutamate dehydrogenase [GLDH], and', 'serum albumin', 'A specialist or hepatology consultation is', 'recommended.', 'International normalized ratio (INR)', 'Fractionate bilirubin, if total bilirubin', '>1.5xULN.', 'Obtain complete blood count with', '113']['2017N331008_06', 'CONFIDENTIAL', '208090', 'differential to assess eosinophilia.', 'Anti-nuclear antibody, anti-smooth muscle', 'antibody, Type 1 anti-liver kidney', 'microsomal antibodies, and quantitative', 'total immunoglobulin G (lgG or gamma', 'globulins).', 'Liver imaging (ultrasound, magnetic', 'resonance, or computerised tomography)', 'and /or liver biopsy to evaluate liver', 'disease; complete Liver Imaging and/or', 'Liver Biopsy eCRF forms.', 'Record the appearance or worsening of', 'clinical symptoms of liver injury, or', 'hypersensitivity, fatigue, decreased', 'appetite, nausea, vomiting, abdominal', 'pain, jaundice, fever, or rash as relevant', 'on the AE report form.', 'Record use of concomitant medications', 'on the concomitant medications report', 'form including acetaminophen, herbal', 'remedies, other over the counter', 'medications.', 'Record alcohol use on the liver event', 'alcohol intake eCRF.', 'CPK - creatine phosphokinase', '1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study intervention for that participant if ALT >3xULN and bilirubin >2xULN.', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT >3xULN and bilirubin >2xULN (>35% direct bilirubin) must be reported as an SAE (excluding', 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Record the date/time of the PK blood sample draw and the date/time of the last dose of study intervention prior to', \"blood sample draw on the eCRF. If the date or time of the last dose is unclear, provide the participant's best\", 'approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in', 'the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are in', 'the SRM.', '114']\n\n###\n\n", "completion": "END"}